Delstrigo seeks reimbursement to join the HIV drug market
By Eo, Yun-Ho | translator Byun Kyung A
21.02.04 16:45:00
°¡³ª´Ù¶ó
0
Clinical trial confirms non-inferior efficacy against EFV-FTC-TDF
Industry reports the drug submitted application in December for the once-daily oral combination drug as a first-line therapy
The pharmaceutical industry reported, MSD Korea has submitted an application for the NHI reimbursement on an once-daily fixed-dose combination tablet Delstrigo (doravirine / lamivudine / tenofovir disoproxil fumarate) treating human immunodeficiency virus type 1 (HIV-1).
The South Korean authority approved Delstrigo as a treatment for HIV-1 infection in adults with no prior antiretroviral treatment experience.
One of the combined agents, doravirine received South Korea¡¯s Ministry of Food and Drug Safety (MFDS) approval as of Nov. 22, 2019, with a brand name
Eo, Yun-Ho(unkindfish@dailypharm.com)
If you want to see the full article, please JOIN US (click)